Protocol Page


	Study ID (Protocol Number)
	AI424-402


	STUDY LOCATIONS*
	Consultive Medicine Daytona Beach, FL 32117 Recruiting	Local Institution Altamonte Springs, FL 32701 Not yet recruiting
	Health For Life Clinic Pllc Little Rock, AR 72207 Recruiting	Local Institution Orlando, FL 32804 Not yet recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Atazanavir/Ritonavir (ATV/RTV) Once a Day (QD) + Raltegravir (RAL) Twice a Day (BID) Stable Switch Study
	STUDY OVERVIEW
	The purpose of this study is to evaluate if HIV-1 infected subjects who are virologically suppressed on a regimen which consists of 2 Nucleoside reverse transcriptase inhibitor's (NRTI) plus any 3rd agent but who are experiencing safety and/or tolerability issues to this regimen will continue to maintain virologic suppression following a switch to a regimen consisting of heat-stable Ritonavir boosted Atazanavir (300/100mg) once daily plus Raltegravir (400mg) twice daily.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.